Serum uric acid levels and renal damage in hyperuricemic hypertensive patients treated with renin-angiotensin system blockers

American Journal of Hypertension

Volumn 23, Issue 6, 2010, Pages 675-680

  Berni, Andrea ^a   Boddi, Maria ^a   Fattori, Elisa Bissoni ^a   Cecioni, Ilaria ^a   Berardino, Sabino ^a   Montuschi, Francesca ^a   Chiostri, Marco ^a   Poggesi, Loredana ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Allopurinol; Blood pressure; Hypertension; Renal resistive index; Renin angiotensin system; Serum uric acid

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; ALBUMINURIA; ARTICLE; CLINICAL ARTICLE; CREATININE CLEARANCE; DOPPLER FLOWMETRY; FEMALE; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY FUNCTION; KIDNEY INJURY; LOGISTIC REGRESSION ANALYSIS; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URIC ACID BLOOD LEVEL;

ADULT; AGED; ALLOPURINOL; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; HYPERURICEMIA; KIDNEY; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RENIN-ANGIOTENSIN SYSTEM; URIC ACID;

EID: 77952546027     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2010.33     Document Type: Article

References (27)

1. Campo C, Ruilope LM, Segura J, Rodicio JL, García-Robles R, Garcia-Puig J. Hyperuricemia, low urine urate excretion and target organ damage in arterial hypertension. Blood Press 2003; 12:277-283.
2. Obermayr R P, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008; 19:2407-2413.
3. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2008; 19:1204-1211.
4. Viazzi F, Leoncini G, Ratto E, Falqui V, Parodi A, Conti N, Derchi LE, Tomolillo C, Deferrari G, Pontremoli R. Mild hyperuricemia and subclinical renal damage in untreated primary hypertension. Am J Hypertens 2007; 20:1276-1282. (Pubitemid 350151695)
5. Tsioufis C, Chatzis D, Vezali E, Dimitriadis K, Antoniadis D, Zervoudaki A, Lalos S, Kallikazaros I, Stefanadis C, Toutouzas P. The controversial role of serum uric acid in essential hypertension: relationships with indices of target organ damage. J Hum Hypertens 2005; 19:211-217.
6. Ruggenenti P, Remuzzi G. Time to abandon microalbuminuria? Kidney Int 2006; 70:1214-1222.
7. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 282:F991-F997.
8. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, Johnson RJ. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40:355-360.
9. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67:1739-1742.
10. Tsouli SG, Liberopoulos EN, Kiortsis DN, Mikhailidis D P, Elisaf MS. Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence. J Cardiovasc Pharmacol Ther 2006; 11:1-15.
11. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
12. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 2007; 27:435-440.
13. Boddi M, Abbate R, Chellini B, Giusti B, Solazzo V, Soft F, Pratesi G, Pratesi C, Gensini G, Zignego AL. HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. Dig Liver Dis 2007; 39 Suppl 1:S55-S60.
14. Mittelstaedt CA. General Ultrasound. Churchill: London, 1992, pp 883-1042.
15. Boddi M, Sacchi S, Lammel RM, Mohseni R, Serneri GG. Age-related and vasomotor stimuli-induced changes in renal vascular resistance detected by Doppler ultrasound. Am J Hypertens 1996; 9:461-466.
16. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359:1811-1821.
17. Pontremoli R, Viazzi F, Martinoli C, Ravera M, Nicolella C, Berruti V, Leoncini G, Ruello N, Zagami P, Bezante G P, Derchi LE, Deferrari G. Increased renal resistive index in patients with essential hypertension: a marker of target organ damage. Nephrol Dial Transplant 1999; 14:360-365.
18. Tublin ME, Bude RO, Platt JF. Review. The resistive index in renal Doppler sonography: where do we stand? AJR Am J Roentgenol 2003; 180:885-892.
19. Ishimura E, Nishizawa Y, Kawagishi T, Okuno Y, Kogawa K, Fukumoto S, Maekawa K, Hosoi M, Inaba M, Emoto M, Morii H. Intrarenal hemodynamic abnormalities in diabetic nephropathy measured by duplex Doppler sonography. Kidney Int 1997; 51:1920-1927.
20. Boddi M, Cecioni I, Poggesi L, Fiorentino F, Olianti K, Berardino S, La Cava G, Gensini G. Renal resistive index early detects chronic tubulointerstitial nephropathy in normo-and hypertensive patients. Am J Nephrol 2006; 26:16-21.
21. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJ, Anker SD, Hambrecht R. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002; 105:2619-2624.
22. Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, MacDonald TM. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002; 87:229-234.
23. Hare JM, Johnson RJ. Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation 2003; 107:1951-1953.
24. Siu Y P, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47:51-59.
25. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16:3553-3562.
26. Perlstein TS, Gumieniak O, Hopkins PN, Murphey LJ, Brown NJ, Williams GH, Hollenberg NK, Fisher ND. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int 2004; 66:1465-1470.
27. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002; 346:913-923.